Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.21	Interim Report - January-September 2021 (GlobeNewswire)
11.11.21	Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones (GlobeNewswire)
09.11.21	Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands (GlobeNewswire)
03.11.21	Karolinska Development’s portfolio company Umecrine Cognition presents new data supporting the development of golexanolone as a treatment of primary biliary cholangitis (GlobeNewswire)
27.10.21	Karolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsia (GlobeNewswire)
25.10.21	Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure (GlobeNewswire)
19.10.21	Karolinska Development's portfolio company Umecrine Cognition to collaborate with University College London to increase insights about golexanolone (GlobeNewswire)
04.10.21	Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI (GlobeNewswire)
09.09.21	Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst (GlobeNewswire)
19.08.21	Interim Report - January-June 2021 (GlobeNewswire)
16.08.21	Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market (GlobeNewswire)
12.08.21	Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program (GlobeNewswire)
22.07.21	Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt (GlobeNewswire)
15.07.21	Karolinska Development’s portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing (GlobeNewswire)
14.07.21	Karolinska Development’s portfolio company Umecrine Cognition raises capital through a successful share issue (GlobeNewswire)
07.07.21	Karolinska Development’s portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical (GlobeNewswire)
07.07.21	Karolinska Development sells its holding in Lipidor AB and receives a net of SEK 4 million (GlobeNewswire)
17.06.21	Karolinska Development expands its portfolio through new investment in AnaCardio (GlobeNewswire)
17.06.21	Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million (GlobeNewswire)
17.06.21	Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia (GlobeNewswire)
15.06.21	Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria (GlobeNewswire)
11.06.21	Karolinska Development’s portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth Market (GlobeNewswire)
10.06.21	Karolinska Development’s portfolio company Biosergen raises SEK 50 million through a successful unit offering and prepares for IPO (GlobeNewswire)
01.06.21	Karolinska Development’s portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparin (GlobeNewswire)
21.05.21	Karolinska Development's portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten